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whose blood expression was altered compared to healthy subjects. In OA, 9
miRNA were up-regulated (including miR-228, miR-574-3p, miR-597) and
9 miRNAs were down-regulated (including miR-150, miR-222, miR-363
and miR-423). None of miRNAs in OA is common with those we found
in RA. Potential targets of miRNAs, speciﬁcally expressed in severe knee
osteoarthritis, appears to be largely involved in the Wnt signaling pathway.
In contrast, the miRNAs expressed differently in the blood of our RA
patients seem to target the elements of the signaling pathway MAP kinase.
Conclusions: Our results suggest that miRNAs may constitute new
biomarkers potential diagnostic interest. In addition, miRNAs could be
involved in the pathogenesis of OA. Further work is ongoing in order to
assess the pathophysiological and the functional role of these miRNAs in
OA.
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STATIN USE IS ASSOCIATEDWITH REDUCED INCIDENCE AND
PROGRESSION OF KNEE OSTEOARTHRITIS
S. Clockaerts1,2 , B. Stricker2, Y.M. Bastiaansen-Jenniskens2, F. Van
Glabbeek1, J.B. Van Meurs2, J.A. Verhaar2, A. Hofman2, G.V. Van Osch2,
S.M. Bierma-Zeinstra2
1Univ. of Antwerp, Edegem, Antwerp, Belgium; 2Erasmus MC, Univ. Med. Ctr.,
Rotterdam, Netherlands
Purpose: Besides biomechanical and genetic alterations, the pathogenesis
of osteoarthritis (OA) may involve inﬂammation, vascular alterations and
dysregulation of lipid metabolism. Statins are drugs capable of modulating
many of these different mechanisms and therefore may have the potential
to act as disease modifying drugs for osteoarthritis. In this study we
hypothesized that statins decrease incidence and progression of knee and
hip OA. To test this hypothesis, we used a large population cohort study.
Methods: 2974 subjects of the Rotterdam Study (a population-based cohort
study), aged 55 years and older were included in this study. X-rays of
the knee and the hip were obtained at baseline and follow up (mean
follow up 6.3 years), and were scored with the Kellgren & Lawrence score
(0=absent OA, 1=doubtful OA, 2=mild OA, 3=moderate OA, 4=severe OA, 5=
prosthesis). Incidence of OA was deﬁned as a Kellgren & Lawrence score
of 0 or 1 and a score of 2 or more at follow up. Progression of OA was
speciﬁed as a Kellgren & Lawrence score of 1, 2 or 3 and increase of 1 or
more. Information on statin use was obtained from detailed computerized
pharmacy data. Use of statins was deﬁned as the daily use of 50% or more
of recommended dose and this for a period of 100 days or more. Data
on potential confounding variables such as age, gender, body mass index,
diabetes mellitus, arterial hypertension, peripheral artery disease, bone
mineral density and total cholesterol level were collected. A multivariate
logistic regression model adjusting for confounding variables was ﬁtted to
calculate odds ratios with conﬁdence intervals. Correlations between right
and left joints were accounted for with generalized estimating equations.
Results: Osteoarthritis (Kellgren & Lawrence score 2 or more) was present
in 546 knees and 323 hips at baseline and in 696 knees and 521 hips at
follow up in 1277 men and 1697 women. Overall, 13.2% of subjects were
deﬁned as statin users. The adjusted odds ratios for incidence of knee OA
in users of statins was 0.40 (95% CI 0.20 - 0.80, p=0.01) and for progression
of knee OA 0.47 (95% CI 0.25 - 0.87, p=0.02). The use of statins was neither
associated with incidence of hip OA (adjusted odds ratio 0.85, 95% CI 0.54 -
1.34, p=0.48), nor with progression of hip OA (adjusted odds ratio 1.13, 95%
CI 0.71 - 1.81, p=0.61).
Conclusions: Statin use is associated with a reduction in incidence and
progression of knee osteoarthritis. Randomized clinical trials in a popula-
tion at risk are needed to examine whether statins could be useful as a
treatment for knee OA.
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EIGHTY-SEVEN PERCENT OF 66 ADULT PATIENTS WITH ADVANCED
OSTEOARTHRITIS OF THE KNEE SUBJECTED TO TREATMENTWITH
INTRA-ARTICULAR INJECTIONS OF HUMAN GROWTH HORMONE AVOID
TOTAL KNEE ARTHROPLASTY
A.R. Dunn
Mt. Sinai Med. Ctr., Miami Beach, FL
Purpose: Intra-articular injections of growth hormone produce Pre-natal
Developmental Healing (PDH). This unique action of growth hormone,
proven in mature rabbits, does not involve bleeding, clot formation or the
in-pouring of inﬂammatory cells. This healing is scar-free and produces
no ﬁbroartilage. The cascade of PDH ﬁrst involves the rejuvenation of
mature subchondral arteries to form fetal fenestrated capillaries which
produce autologous stem cells. These are the same vessels which produce
the fetal cartilage skeleton in utero. These stem cells are signaled to form
chondrocytes and by the completion of the PDH cascade real articular
cartilage with vertical parallel columns of chondrocytes form with arcades
at the surface and 100 per cent bonding to host bone. This method is the
ﬁrst to regrow real articular cartilage.
Method: Sixty-six adults with advanced osteoarthritis of the knee were
treated with intra-articular injections of Human Growth Hormone (HGH).
One-third required arthroscopic debridement and abrasion of eburnated
bone on the condyles.
Each knee received from eight to ﬁfteen weekly injections of Human
Growth Hormone (HGH). Dosage varied according to the size of the knee.
All patients were required to be non weight bearing on the treated side for
the duration of the treatment. Patients were required to perform simple
exercises at home. Less than one-fourth required physiotherapy.
There were no complications or side effects from the surgery or the
injections of human growth hormone (HGH)
Results: Eighty-seven percent of the patients had good to excellent results.
Several before and after X-rays of the HGH treated knees will be presented.
These X-rays demonstrate an increase of the joint spaces from 2 to 5 mm.
Evaluation with the IKDC format will be presented in graph form. There
were no infections, complications, side effects, deep vein thrombosis, pul-
monary embolism or deaths. The patients who did not respond were no
worse. Six per cent went on to have total knee arthroplasty (TKA). the
remainder were undecided about having TKA.
Conclusions: A safe, cost-effective alternative to TKA is presented. There
were no complications such as those which arise from TKA. The cost of
treatment with HGH even including arthroscopic surgery is one-fourth that
of TKA. And the additional costs of treating infected TKA are completely
avoided. Many orthopedic surgeons are concerned that their livelihood
will be adversely impacted by loss of TKA surgery; however, they should
consider that there is no need for hospital rounds, or need to treat infec-
tions and other serious complications. Insurance companies and Medicare
or other government insurance programs can save billions of dollars every
year by avoiding costly TKA surgeries at $35,000.00 per TKA.
The author recommends that this HGH treatment, which he named IAGH,
be the ﬁrst choice for treating advanced osteoarthritis of the knee.
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EFFECT OF ROSEMARY EXTRACT AND RELATED FLAVONOID CARNOSOL
ON CHONDRO-PROTECTION AND ON THE BONE-CARTILAGE CROSSTALK
M.-N. Horcajada1, C. Sanchez2, F. Scalfo1, L. Ameye1, Y. Henrotin2,
E. Offord1
1Nestle, Lausanne, Switzerland; 2Univ. of Liège, Liège, Belgium
Purpose: The aim of this work was to evaluate the effect of Rosemary
extract (P31, Robertet, France) and one of its associated ﬂavonoids, carnosol
(Sigma, Buchs, Switzerland) on metabolic functions of chondrocytes and
osteoblasts, as well as on the bone-cartilage crosstalk.
Methods: Content of carnosol in rosemary extract P31 was around 7%.
Rosemary extract and carnosol eﬃcacy were assessed at various concentra-
tions in the different experiments: 3-25μg/ml and 6nM-30μM, respectively.
Normal and Osteoarthritic (OA) human chondrocytes were cultured in al-
ginate beads for 12 days in presence or absence of both compunds.
Production of aggrecan (AGG), stromelysin (MMP-3), interleukin (IL)-6 and
nitric oxide were analyzed. Isolated human osteoblasts from sclerotic (SC)
or non sclerotic (NSC) subchondral bone were cultured for 3 days in
presence or absence of both compounds and alkaline phosphatise (AP)
activity, interleukin-6 and prostaglandin PGE2 levels were determined.
Finally, subchondral osteoblasts coming from NSC or SC areas were incu-
bated with rosemary extract or carnosol for 72h before coculture with OA
chondrocytes in alginate beads. After 4 days of co-culture, we analyzed
AGG content of the alginate beads, and chondrocytes gene expression of
AGG, type II collagen, MMP-3, MMP-13 and osteopontin (OPN).
Results: In both OA and normal chondrocytes, AGG production was signif-
icantly increased with 9 μM carnosol. MMP-3 and nitric oxide production
was signiﬁcantly decreased by both compounds, in a dose-dependent
manner, while only carnosol signiﬁcantly decreased the cytokine IL-6
secretion. Regarding osteoblast cultures, AP activity was not affected in the
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presence of carnosol in SC and NSC cultures and highly reduced in both
cell cultures in presence of rosemary extract.Carnosol was able to reduce
IL-6 production by both SC and NSC osteoblasts at all doses tested while
rosemary extract was eﬃcient only on osteoblasts from the NSC area. Both
compounds were also able to signiﬁcantly decrease PGE2 production by
osteoblasts from both subchondral areas.
In the coculture experiments, carnosol pre-incubated in NSC and SC os-
teoblasts signiﬁcantly increased AGG and signiﬁcantly decreased MMP-3
and OPN gene expression by chondrocytes. Rosemary extract only signif-
icantly decreased MMP-3 expression by chondrocytes in presence of SC
osteoblasts.
Conclusions: In our experimental conditions, we showed that carnosol,
through anti-inﬂammatory mechanisms, was able to reduce cartilage
matrix breakdown and enhance its formation, more consistently than
rosemary extract, at physiological concentrations.
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MESENCHYMAL STEM CELLS IN OA PATIENTS: DOWNREGULATION OF
WNT SIGNALING PATHWAY AND MIR335
B. Fernandez-Gutierrez1 , E. Villafuertes1, J. Hoyas1, M. Gonzalez2,
P. Tornero-Esteban1
1Hosp. Clinico San Carlos, Madrid, Spain; 2CNIC, Madrid, Spain
Purpose: Osteoarthritis (OA) is a disease characterized by progressive
degeneration of articular cartilage and bone. Homeostasis of the articular
tissues depends largely on the ability of self-renewal and differentiation
of mesenchymal stem cells (MSCs) into different cell types of mesodermal
lineage. This process is mediated by activation and suppression of differ-
ent genes controlling post-transcriptional regulation of gene expression.
miRNAs (short 20-24 nt non-coding RNAs) are key molecules affecting
both the stability and translation of mRNAs. The expression of miR335
in control Bone Marrow-MSCs (BM-MSCs) has been previously connected
with the canonical Wnt signaling pathway. According to these evidences,
our purpose is to study, in BM-MSCs from OA patients, the canonical Wnt
pathway and the expression of miR335.
Methods: Eight OA patients and eight controls were included. BM-MSCs
from OA patients were obtained at the time of total joint replacement
surgery of hip OA. BM-MSCs from controls were obtained at the time
of surgery of subcapital hip fracture without OA signs and without
osteoporosis.
Cells were isolated and expanded until the third passage. RNAs were ex-
tracted to perform comparative gene expression proﬁling using the Agilent
4×44 whole-genome expression array and the Agilent Human microRNA.
After data ﬁltering, background correction and, normalization, differentially
expressed genes at p<0.05 level of signiﬁcance showing more than, or less
than, two-fold differences, were eligible. To determine miRNA expressions,
RNA samples from ﬁve patients and ﬁve controls were hibridized and
analyzed using the Microarray v2.0 (G4470B, Agilent). MEST gene, that con-
trols miR335 expression, was analyzed in the Agilent 4×44 whole-genome
expression array and validated by quantitative PCR (qPCR).
Results: Wnt pathway was clearly defective in MSCs from OA origin. Major
differences showed a signiﬁcant downregulation of 11 genes related to the
Wnt pathway, these include CCND2, CSNK2A1, DVL1, DVL3, FZD3, LRP6,
NLK, PPP3CC, SENP2, SFRP2 and WNT4. In addition, in all samples miR335
expression levels were diminished around 50% in OA patients compared to
expression levels found in controls.
MEST gene was clearly downregulated in the Agilent 4×44 whole-genome
expression array and this result is concordant with MEST qPCR results.
Conclusions: Our results suggest that expression of miR335 in MSCs is
connected with Wnt signaling pathway also in OA patients. We hypothesize
that the diminished miR335 expression and Wnt signalling pathway in OA
could be a part of the altered function of BM-MSCs in OA patients.
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MIR-7 ANDMIR-130B ARE DIFFERENTIALLY REGULATED DURING
MESENCHYMAL STEM CELL COMMITMENT
G. Palmer1, L. Danielson2, M. Attur1, S.B. Abramson1, E. Hernando2
1NYUHosp. for Joint Diseases, New York, NY; 2NYU Langone Med. Ctr., New
York, NY
Purpose: Stem cell-based therapies aimed at introducing progenitor cells
into cartilage lesions hold great promise for the restoration of damaged
articular surfaces following joint injury or osteoarthritis. Key to the gen-
eration of a functional repair tissue is the controlled differentiation into
the desired phenotype. To this end microRNAs (miRNAs) may be important
molecules that regulate this process. By acting as transcriptional repressors,
their modulation during differentiation may enable commitment to a spe-
ciﬁc lineage by suppressing the expression of other lineage markers. In this
study we proﬁled Mesenchymal Stem Cells (MSCs) for miRNA expression
following induction into the chondrocyte (C), osteoblast (O) and smooth
muscle (SM) lineages.
Methods: Cell culture: Human bone marrow derived MSCs were obtained
from NIH or from the discarded hips of patients undergoing joint replace-
ment surgery. Differentiation: SM differentiation was induced by treating
monolayer cultures with 1 μM thromboxane-A2 [DP1] in the presence of
0.25% serum. C differentiation was induced by seeding MSCs in aggregate
cultures in the presence of 1% ITS, dexamethasone (10-7 M) and TGF-β1
(10 ng/ml). O differentiation was induced by treatment of monolayer
cultures with dexamethasone (10-7 M), ascorbate (37.5 μg/ml) and beta-
glycerolphosphate (10 mM) in the presence of 10% serum. miRNA proﬁling:
At various timepoints after induction, miRNA was extracted for analysis.
miRNA proﬁling was performed by microarray (Agilent) or qPCR based
assay (SA Biosciences). In all cases differentiation was conﬁrmed by qPCR
of lineage speciﬁc markers and histology.
Results: Among 376 miRNA probes, we noted differential regulation of
two miRNAs among O, SM and C lineages. Following SM and C dif-
ferentiation, miR-7 expression was down-regulated up to 6.9-fold and
3-fold respectively. Conversely, during O differentiation, its expression was
induced approximately 7-fold. Analysis of theoretical mRNA targets us-
ing TargetScan online software (www.targetscan.org) identiﬁed conserved
sites in several genes associated with chondrocyte and myoblast lineages.
Putative chondrogenic targets were found to include COL2A1, IGFR1, and
GDF5, while potential smooth muscle modulators included EGFR1, PIK3CD,
IRS1/IRS2, KLF4, CNN3 and IGF1R. Following a similar trend to miR-7,
miR-130b was down-regulated up to 3.2-fold and 3.1-fold in C and SM
differentiation respectively, while O differentiation induced its expression
2-fold. TargetScan analysis identiﬁed putative chondrogenic targets, TGF-
BRII, Sox5, BMP-2 and IGF1; Potential smooth muscle regulators included
ESR1, TGF-BRII, MBLN1, TGFBR1 and IGF2BP1. Together these observations
suggest that miR-7 and miR-130b act to negatively regulate myogenic and
chondrogenic cell fates via regulation of lineage speciﬁc genes.
Conclusion: Our ﬁndings suggest that miR-7 and miR-130b, via the target-
ing of lineage speciﬁc molecules, regulate cell fate in adult human MSCs
by inhibiting smooth muscle and chondrocyte differentiation, thereby
promoting ‘default’ differentiation into the osteoblast lineage.
[DP1]0.25% FBS 24 hours prior to addition of 1.0μM of the TxA2 chemical
analog U46619
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BOVINE PRIMARY CHONDROCYTES STIMULATE CARTILAGINOUSMATRIX
PRODUCTION BY HUMAN EMBRYONIC STEM CELLS
N. Ahmed1,2, D.W. Taylor1,2, G. Keller3, M.D. Grynpas1,2, R. Kandel1,2
1Mount Sinai Hosp., Toronto, ON, Canada; 2CIHR-BioEngineering of Skeletal
Tissues Team, Toronto, ON, Canada; 3McEwen Ctr. for Regenerative Med., Univ.
Hlth.Network, Univ. of Toronto, Toronto, ON, Canada
Purpose: A requirement of in vitro tissue generation for cartilage repair is
suﬃcient number of cells which is diﬃcult to attain from sparsely cellular
cartilage tissue. Thus proper selection of cell source is an impending
problem for cartilage tissue engineering. Optional cell types are chondro-
cytes, marrow progenitor cells and embryonic stem cells. Use of human
embryonic stem cells (hES) for cartilage tissue engineering is still in its
infancy mainly because the existing techniques do not render functionally
stable cartilage tissue. To push hES cells towards a speciﬁc lineage cues
are required from growth factors, media and culture conditions. Previ-
ously we have shown that co-culture of dedifferentiated chondrocytes
with small numbers of primary chondrocytes induces redifferentiation
in passaged dedifferentiated cells. In this study we show for the ﬁrst
time a novel culture approach where hES cells when co-cultured with
bovine primary chondrocytes (bP0) exhibit the ability to deposit functional
three-dimensional cartilaginous matrix.
Methods: Cell preparation: Bovine articular cartilage (6-9 months old)
was harvested from metacarpo-phalangeal joints and chondrocytes were
isolated by sequential enzymatic digestion. GFP labeled-human embryonic
